Psoriatic Arthritisにおける感染の比較リスクと併用標的治療の流行
Alexander Wu1, Arianna Zhang2, Yujia Guo3
1Department of Dermatology, University of Texas Southwestern Medical Center, Dallas.
JAMA dermatology
|August 20, 2025
まとめ
約1% の患者で使用されています. この研究では,標準治療と比較して,重篤なまたは好機的な感染症の有意な増加は認められず,潜在的に安全な治療の選択肢を示唆した.
科学分野:
- リウマトロジ
- 免疫学
- 薬理学について
背景:
- 併用標的治療の安全性に関するデータは限られているため,疹関節炎 (PsA) の管理は困難です.
- システム免疫調節療法の組み合わせは,他の免疫媒介疾患において有望である.
研究 の 目的:
- PsAの成人の患者における併用標的治療の有効性と安全性を評価する.
- 併用標的治療と標準治療に関連した感染リスクを比較する.
主な方法:
- IBM MarketScan Commercial Claims Database (2015-2024) を用いた後向きコホート研究について
- 認定されたクレームアルゴリズムを用いてPsAを特定した成年者
- 安全性分析のために,標的治療を併用した患者と標準治療 (2: 1 の比率) を比較した.
主要な成果:
- 商業的に保険に入っているPSA患者の約1%が,併用標的治療を受けた.
- TNF阻害剤やIL-17阻害剤とアプレミラストを併用した併用薬は一般的でした.
- 標準療法と比較して,併用療法群では,入院を必要とする重篤な細菌性感染症の有意な増加は観察されなかった.
結論:
- 標的治療の組み合わせは,PsA患者の小さなサブセットによって利用されます.
- 現在のデータでは,PsAに対する併用標的治療は重篤な感染症のリスクを有意に増加させないことが示唆されています.
- これらの安全性発見を確認するために,さらなる大規模な研究が必要である.
関連する概念動画
Factors Affecting the Risk of Infection
12.3K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
12.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Relative Risk
342
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
342
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


